Abstract
The XPF-ERCC1 heterodimer is a structure-specific endonuclease that is essential for nucleotide excision repair (NER) and interstrand crosslink (ICL) repair in mammalian cells. However, whether and how XPF binding to ERCC1 is regulated has not yet been established. Here, we show that TIP60, also known as KAT5, a haplo-insufficient tumor suppressor, directly acetylates XPF at Lys911 following UV irradiation or treatment with mitomycin C and that this acetylation is required for XPF-ERCC1 complex assembly and subsequent activation. Mechanistically, acetylation of XPF at Lys911 disrupts the Glu907-Lys911 salt bridge, thereby leading to exposure of a previously unidentified second binding site for ERCC1. Accordingly, loss of XPF acetylation impairs the damage-induced XPF-ERCC1 interaction, resulting in defects in both NER and ICL repair. Our results not only reveal a mechanism that regulates XPF-ERCC1 complex assembly and activation, but also provide important insight into the role of TIP60 in the maintenance of genome stability.
Subject terms: Cancer, Cell biology
The XPF-ERCC1 heterodimer is an endonuclease involved in nucleotide excision (NER) and interstrand crosslink (ICL) repair in mammalian cells. Here, the authors provide insights into its regulation by revealing that TIP60 regulates XPF-ERCC1 complex assembly and activation.
Introduction
The integrity of genomic DNA is continuously assaulted by endogenous and exogenous DNA-damaging agents that cause various types of DNA lesions1,2. These DNA lesions can directly compromise vital cellular processes such as transcription, translation, and replication1,2. To cope with the detrimental effects of DNA damage, living organisms have evolved a range of highly conserved surveillance and repair mechanisms, such as nucleotide excision repair (NER), interstrand crosslink (ICL) repair, and DNA double-strand break (DSB) repair1,2. Defects in the regulation of any of these mechanisms often lead to genome instability, a hallmark of cancer and aging1,2.
The XPF-ERCC1 complex is a structure-specific endonuclease that plays an essential role in both NER and ICL repair3–9. Mutations in XPF-ERCC1 have been associated with several human inherited disorders, including Cockayne syndrome, xeroderma pigmentosum, cerebro-oculo-facio-skeletal syndrome, and Fanconi anemia4,10–13. As a nuclease, XPF‐ERCC1 is able to cleave a variety of DNA substrates, such as bubbles, flaps, and splayed arms14–22. Biochemical and structural studies have revealed that XPF and ERCC1 form a heterodimer in eukaryotic cells through the interaction of their conserved C-terminal tandem helix–hairpin–helix (HhH) motifs23–26. However, whether and how XPF binding to ERCC1 is regulated has not yet been established.
TIP60 is an acetyltransferase involved in the regulation of a wide variety of cellular activities, including gene transcription, chromatin remodeling, and DNA damage repair27–29. For instance, TIP60 directly acetylates ATM at Lys3016 to enhance ATM kinase activity, thereby regulating the cellular response to DSBs30. TIP60 has also been suggested to regulate the cellular response to ultraviolet (UV) irradiation, but the exact role of its acetyltransferase activity in this process remains largely unexplored31–34. Moreover, another study showed that TIP60 directly interacted with the Fanconi anemia protein FANCD2 and was critical for ICL repair35. However, downregulation of TIP60 did not affect FANCD2 mono-ubiquitination or its localization to DNA damage sites following treatment with mitomycin C (MMC)35, indicating that TIP60 may facilitate ICL repair by a yet-unknown mechanism.
In this study, we identify a regulatory mechanism underlying XPF-ERCC1 complex assembly and function by TIP60-dependent acetylation. We show that the XPF-ERCC1 interaction increases following UV irradiation or treatment with MMC. The damage-induced XPF-ERCC1 interaction requires TIP60-dependent acetylation of XPF at Lys911, which disrupts the Glu907-Lys911 salt bridge, thereby exposing a previously unidentified second binding site for ERCC1. Finally, we reveal that the damage-induced XPF-ERCC1 interaction is necessary for both NER and ICL repair. Our results provide mechanistic insight into the role of TIP60 in the maintenance of genome stability.
Results
TIP60 is required for efficient nucleotide excision repair
To investigate the role of TIP60 in the repair of UV-induced DNA damage, we employed two short hairpin RNAs (shRNAs) to suppress endogenous TIP60 expression in HeLa cells. As previously reported, downregulation of TIP60 not only impairs ionizing radiation (IR)-induced ATM activation, but also causes hypersensitivity to the DNA crosslinking agent MMC (Fig. 1a and Supplementary Fig. 1A)30,35. Strikingly, TIP60 depletion also rendered cells more sensitive to UV irradiation, indicating that TIP60 might be involved in the repair of UV-induced lesions (Fig. 1b).
Translesion DNA synthesis (TLS) and NER are the two major DNA damage tolerance/repair pathways that confer cellular resistance to UV irradiation36,37. To investigate how TIP60 contributes to the tolerance/repair of UV damage, we first examined whether depletion of TIP60 affected UV-induced proliferating cell nuclear antigen (PCNA) mono-ubiquitylation, a central event in the TLS pathway38. As shown in Supplementary Fig. 1B, following UV irradiation, the levels of PCNA mono-ubiquitylation in TIP60-depleted cells were comparable to that in wild-type cells. In line with this, downregulation of TIP60 did not affect UV-induced polymerase eta (Polη) foci formation (Supplementary Fig. 1C, D). These findings suggest that TIP60 is not required for TLS and thus may play a role in the NER pathway.
Cyclobutane pyrimidine dimers (CPDs) and pyrimidine-(6–4)-pyrimidone photoproducts (6-4PPs) are two predominant types of UV-induced DNA lesions and are primarily repaired by the NER pathway39. We then compared the rates of repair of CPDs and 6-4PPs in UV-irradiated wild-type and TIP60-depleted cells at various time points post-irradiation. As shown in Fig. 1c, d and Supplementary Fig. 1E, F, compared with wild-type cells, TIP60-depleted cells displayed a much-delayed removal rate of CPDs and 6-4PPs, indicating that TIP60 is required for efficient NER. To determine whether the acetyltransferase activity of TIP60 is essential for its function in this process, we treated cells with MG149 or NU9056, two small-molecule inhibitors of TIP60. As shown in Fig. 1e, f and Supplementary Fig. 1G, H, inhibition of TIP60 acetyltransferase activity resulted in similar NER defects as TIP60 depletion. More importantly, TIP60-depleted cells expressing the acetyltransferase-inactivating mutant, Q377E/G380E (TIP60-MT), also exhibited much-delayed removal of CPDs and 6-4PPs compared with that of cells expressing wild-type TIP60 (TIP60-WT) (Fig. 1g, h and Supplementary Fig. 1I). Taken together, these results suggest that the acetyltransferase activity of TIP60 is indispensable for its function in NER.
TIP60 interacts with and acetylates XPF
To gain insight into how TIP60 participates in the NER pathway, we purified proteins interacting with TIP60 using tandem affinity purification. In addition to these known TIP60-interacting proteins such as RUVBL1, RUVBL2, and DMAP1, we also identified several protein complexes associated with the DNA damage response (Supplementary Data 1). Notably, one of these complexes, the XPF-ERCC1 complex is related to the NER pathway (Fig. 2a and Supplementary Data 1). The presence of XPF and ERCC1 in TIP60 purification was further confirmed by western blots (Fig. 2b). Moreover, in vitro GST pull-down assays with recombinant GST-tagged TIP60 and MBP-tagged XPF or ERCC1 purified from E. coli demonstrated that TIP60 directly interacted with XPF but not ERCC1 (Fig. 2c and Supplementary Fig. 2A, B). These results suggest that TIP60 associates with the XPF-ERCC1 complex primarily through XPF.
To explore whether XPF and/or ERCC1 could be the substrate(s) for the acetyltransferase TIP60, HEK293T cells were co-transfected with Myc-tagged TIP60 together with SFB-tagged XPF or ERCC1. Cell lysates were then subjected to pull-down assays with S protein beads and immunoblotted with a pan-anti-acetyl-lysine antibody. As shown in Fig. 2d, XPF, but not ERCC1, was efficiently acetylated by TIP60. By contrast, GCN5 and PCAF, were unable to acetylate XPF in similar assays, demonstrating the specificity of TIP60 in XPF acetylation (Fig. 2e). Furthermore, TIP60 acetylated XPF in a dose-dependent manner (Fig. 2f). More importantly, the enzymatically inactive mutant of TIP60 failed to acetylate XPF (Fig. 2g).
We next wanted to assess whether endogenous XPF could be acetylated. Since our homemade anti-XPF antibody was unable to precipitate the endogenous XPF protein, we fused an SFB tag onto the C-terminus of the endogenous XPF gene using the recombinant adeno-associated virus-based knock-in approach40,41. With this method, the endogenous XPF protein can be recognized by the anti-Flag antibody. We thus incubated the lysates derived from XPF-SFB knock-in HeLa cells with anti-Flag antibody and immunoblotted the resulting immunoprecipitates with the pan anti-acetyl-lysine antibody. As shown in Fig. 2h, acetylation of endogenous XPF was clearly detected in cells treated with the deacetylase inhibitors trichostatin A (TSA) and nicotinamide (NAM), but not in untreated control cells.
We further used the purified E. coli-expressed MBP-tagged XPF and GST-tagged TIP60 to perform in vitro acetylation assays. As shown in Fig. 2i, XPF was acetylated by TIP60, but not by the GST tag, in vitro.
XPF is acetylated at lysine 911
To identify the potential acetylation site(s) on XPF, we purified stably expressed XPF from HEK293T cells pretreated with the deacetylase inhibitors TSA and NAM. Mass spectrometry analysis revealed two lysine residues (Lys871 and Lys911) as candidate acetylation sites on XPF (Fig. 3a). We therefore mutated each lysine residue into arginine (K871R or K911R) to test which residue was acetylated. As shown in Fig. 3b, the K911R mutant, but not the K871R mutant, completely lost its ability to be acetylated by TIP60. Moreover, the K911R mutant interacted with TIP60 as efficiently as wild-type XPF and the K871R mutant (Fig. 3c). To further confirm the specific acetylation at Lys911 by TIP60, we carried out an in vitro acetylation assay using the purified K911R mutant. As shown in Fig. 3d, wild-type XPF, but not the K911R mutant, was acetylated by TIP60 in vitro. These results suggest that Lys911 is the major acetylation site of XPF. Of note, Lys911 of XPF is embedded in an acetylation consensus sequence KXXXK/R (residues 911–915), and is evolutionarily conserved (Fig. 3e). To date, mutation of XPF at Lys911 has not been reported in XP-F patients. We further generated an antibody specific to acetylated Lys911 and verified its specificity by dot blot assays (Fig. 3f). As expected, the site-specific AcK911-XPF antibody recognized wild-type XPF but not the K911R mutant (Fig. 3g).
SIRT1 interacts with and deacetylates XPF
Lysine acetylation is a highly dynamic and reversible process. To identify the specific deacetylase(s) responsible for XPF deacetylation, we generated a HEK293T cell line stably expressing SFB-tagged XPF and performed tandem affinity purification to identify XPF-associated proteins. In addition to known XPF-associated proteins such as ERCC1 and SLX4, we also found that the deacetylase SIRT1 existed in XPF protein complexes (Fig. 4a and Supplementary Data 2). We thereby confirmed the SIRT1-XPF interaction by co-immunoprecipitation experiments. As shown in Fig. 4b, c, SIRT1 interacted with XPF in both endogenous and overexpression systems. We further performed in vitro GST pull-down assays and found that XPF interacted with SIRT1 directly (Fig. 4d). The direct interaction of XPF and SIRT1 prompted us to examine whether SIRT1 has a direct role in the regulation of XPF deacetylation. We co-transfected SIRT1 together with XPF and TIP60 for use in the acetylation assay. As shown in Fig. 4e, overexpression of wild-type SIRT1, but not the catalytic-inactive H363Y mutant (SIRT-HY), resulted in the deacetylation of XPF in cells. We further tested whether SIRT1 could directly deacetylate XPF in vitro. XPF was first acetylated in the in vitro acetylation assay using the recombinant protein. Acetylated XPF was then used as a substrate in the SIRT1 deacetylation assay. As shown in Fig. 4f, XPF was efficiently deacetylated by recombinant SIRT1 in vitro. In addition, depletion of SIRT1 by specific shRNA or inhibition of SIRT1 activity by chemical inhibitor led to a dramatic increase in the acetylation of endogenous XPF (Fig. 4g, h). More importantly, other nuclear localized sirtuins including SIRT2, SIRT6, and SIRT7 failed to deacetylate XPF (Supplementary Fig. 3). Together, these results suggest that SIRT1 is a bona fide XPF-interacting protein and mediates XPF deacetylation.
XPF acetylation increases in response to UV and MMC
We next examined whether the acetylation of XPF can be regulated by DNA damage. As shown in Fig. 5a, b, both UV irradiation and MMC treatment caused a dramatic increase in the acetylation levels of ectopically expressed and endogenous XPF. By contrast, the levels of acetylated XPF were not obviously affected by IR irradiation, the DNA topoisomerase I inhibitor camptothecin, or the DNA replication inhibitor hydroxyurea. Furthermore, UV irradiation and MMC treatment increased XPF acetylation in a dose-dependent manner (Fig. 5c and Supplementary Fig. 4A). Interestingly, UV-induced XPF acetylation at lysine 911 only occurs on a small fraction (about 25%) of total XPF (Supplementary Fig. 4B).
To determine whether UV-induced XPF acetylation was dependent on the acetyltransferase TIP60, we downregulated TIP60 expression in cells by TIP60-specific shRNA. As shown in Fig. 5d, depletion of TIP60 significantly prevented UV-induced XPF acetylation. Similar results were obtained when cells were treated with the TIP60-specific inhibitors MG149 or NU9056 (Fig. 5e).
Given that XPF interacted with TIP60 and SIRT1 directly and UV irradiation stimulated acetylation of XPF, we speculated that UV irradiation may alter the interaction of XPF with TIP60 or SIRT1. Surprisingly, the interaction of XPF and TIP60 or SIRT1 was unaffected following UV irradiation (Supplementary Fig. 4C, D), indicating that other mechanisms may exist.
Previous studies have shown that Deleted in Breast Cancer-1 (DBC1) interacts with SIRT1 directly and thus inhibits its deacetylase activity42,43. Interestingly, genotoxic stress, including IR, etoposide, and H2O2, was able to enhance the SIRT1-DBC1 interaction44. We thus examined whether UV irradiation or MMC treatment could also modulate the SIRT1-DBC1 interaction, thereby inhibiting SIRT1 activity and increasing XPF acetylation. Indeed, following UV irradiation or MMC treatment, DBC1 bound more tightly to SIRT1 (Fig. 5f and Supplementary Fig. 4E).
XPF acetylation facilitates XPF-ERCC1 complex assembly
It has been well established that XPF and ERCC1 form a heterodimer through the interaction of their conserved C-terminal tandem HhH motifs23–26. Since Lys911 is highly conserved among species and is located close to the HhH motifs of XPF, we hypothesized that TIP60-mediated acetylation of XPF may affect XPF-ERCC1 complex assembly. To test this, we first examined whether the XPF-ERCC1 interaction is regulated by UV irradiation or MMC treatment. As shown in Fig. 6a and Supplementary Fig. 5A, the XPF-ERCC1 interaction increased following UV irradiation or MMC treatment. Interestingly, and consistent with the observation that formation of the XPF-ERCC1 heterodimer is essential for the stability of both proteins, the protein levels of both XPF and ERCC1 increased following UV irradiation or MMC treatment (Supplementary Fig. 5B, C). Moreover, TIP60 depletion or inhibition of TIP60 acetyltransferase activity abolished the increase in XPF and ERCC1 protein levels induced by UV irradiation (Fig. 6b, c). Conversely, SIRT1 depletion or inhibition of SIRT1 deacetylase activity resulted in a dramatic increase in the protein levels of XPF and ERCC1 even in the absence of DNA damage (Fig. 6d and Supplementary Fig. 5D). Importantly, downregulation of TIP60 or SIRT1 had no effect on the mRNA levels of both XPF and ERCC1 (Supplementary Fig. 5E, F).
We next determined whether acetylation of XPF is required for the damage-induced interaction of XPF and ERCC1. As shown in Fig. 6e, loss of Lys911 acetylation of XPF abolished the UV-induced XPF-ERCC1 interaction without affecting the constitutive interaction. In addition, the acetylation-mimic mutant K911Q interacted with ERCC1 to a greater extent than wild-type XPF in both the absence and presence of UV damage (Fig. 6e). In contrast, substitution of a nearby lysine residue Lys913, Lys915, or Lys916 with Gln (K913Q, K915Q, or K916Q) did not show obviously enhanced binding to ERCC1 (Supplementary Fig. 5G). Furthermore, in our western blotting experiments, we routinely found that the expression levels of the K911R mutant were much lower than that of wild-type XPF and the K911Q mutant (Supplementary Fig. 5H). These results suggest that TIP60-mediated acetylation of XPF at Lys911 facilitates XPF-ERCC1 complex assembly. Consistent with this conclusion, knockdown of TIP60 reduced the recruitment of XPF to UV-induced DNA damage sites (Supplementary Fig. 5I). In contrast, TIP60 depletion had no effect on the recruitment of the upstream NER factors including XPA, XPB, and XPC to UV lesions8 (Supplementary Fig. 5I).
XPF acetylation exposes a second binding site for ERCC1
In addition to increasing the hydrophobicity of the lysine side chain, lysine acetylation often induces a conformational change by neutralizing the positive charge of the amino acid. Interestingly, in the nuclear magnetic resonance structure (PDB:1z00)23, Lys911 of XPF is positioned in the immediate vicinity of Glu907, indicating a direct salt bridge between the positively charged Lys911 and the negatively charged Glu907 (Fig. 6f). More strikingly, structural analysis revealed that the corresponding region in ERCC1 (amino acids 221–228) is mostly composed of negatively charged as well as hydrophobic residues, which complement well with the positively charged and hydrophobic residues surrounding acetylated Lys911 (amino acids 911–916) (Fig. 6f). Given that acetylation of XPF enhances its interaction with ERCC1, we hypothesized that this acetylation may eliminate the positive charge of Lys911 and disrupt the electrostatic interaction with Glu907, thereby exposing a second binding site for ERCC1. To test this hypothesis, we first mutated the negatively charged glutamic acid residue to alanine (E907A) in XPF and examined its interaction with ERCC1. Similar to the K911Q mutant, the XPF E907A mutant also exhibited enhanced interaction with ERCC1 regardless of UV irradiation (Fig. 6g). Furthermore, substitutions of the positively charged residues (K913A, K915A, and K916A) with neutral uncharged residues in XPF abolished the UV-induced interaction of XPF and ERCC1 (Fig. 6h). More importantly, the acetylated Lys911 peptide (Ac-K911) alone, but not the nonacetylated Lys911 peptide (K911), was able to pull-down endogenous ERCC1 in the absence of UV damage (Fig. 6i). These results suggest that acetylated Lys911 and its surrounding residues in XPF provide a second binding site for ERCC1.
Next, we examined whether the region in ERCC1 (amino acids 221–228) is essential for the UV-induced XPF-ERCC1 interaction. We generated an ERCC1 deletion mutant lacking this region and performed co-immunoprecipitation experiments. As shown in Fig. 6j, deletion of this region abolished the UV-induced XPF-ERCC1 interaction. Consistently, substitutions of the negatively charged residues (D221A, E225A, and E228A) or hydrophobic residues (L223A, M224A, and L227A) with neutral uncharged residues in this region of ERCC1 also abolished the UV-induced XPF-ERCC1 interaction (Supplementary Fig. 5J). Given that mutation at K913, but not K915 or K916 in XPF, diminished UV-induced XPF-ERCC1 interaction (Supplementary Fig. 5G), we speculate that the Lys913 residue of XPF is critical for its interaction with this region in ERCC1. Together these results suggested that, while the HhH motifs present in both proteins mediate the constitutive XPF-ERCC1 interaction, acetylated Lys911 and the surrounding residues in XPF and the region in ERCC1 (amino acids 221–228) contribute to their stress-induced interaction.
XPF acetylation is critical for NER and ICL repair
To investigate whether XPF acetylation is required for NER, we knocked out XPF in HeLa cells by CRISPR/Cas9. As expected, XPF-deficient cells exhibited hypersensitivity to UV irradiation and a much slower removal rate of both CPDs and 6-4PPs when compared with wild-type cells (Fig. 7a–c and Supplementary Fig. 6A–D). Notably, the defects caused by loss of XPF were largely reversed by re-expression of wild-type XPF or the acetylation-mimic mutant K911Q, but not by the acetylation-defective mutant K911R, indicating that XPF acetylation is critical for efficient removal of UV-induced DNA lesions (Fig. 7a–c and Supplementary Fig. 6A–D). In addition, inhibition of TIP60 in XPF-deficient cells did not show any additional defects in the repair of CPDs and 6-4PPs, suggesting that XPF and TIP60 operate in the same pathway (Fig. 7d, e and Supplementary Fig. 6E). More strikingly, in XPF-deficient cells, expression of the K911Q mutant, but not wild-type XPF or the K911R mutant, was able to largely reverse the NER defects caused by TIP60 inhibition (Fig. 7f, g and Supplementary Fig. 6F). These results suggest that TIP60 promotes NER by directly acetylating XPF.
In addition to its essential role in NER, the XPF-ERCC1 complex has also been implicated in the repair of interstrand crosslink damage. We therefore tested whether XPF acetylation is important for ICL repair. As shown in Fig. 7c, knockout of XPF led to hypersensitivity to MMC treatment as expected. Interestingly, re-expression of wild-type XPF, but not the K911R mutant, was able to reverse the defects in XPF-deficient cells (Fig. 7c). More importantly, similar to wild-type XPF, the K911Q mutant was also able to reverse the defects caused by XPF deficiency, indicating that TIP60-mediated acetylation of XPF at Lys911 is critical for ICL repair (Fig. 7c).
Discussion
Despite the importance of TIP60 in the cellular response to UV irradiation and ICL damage, little is known about the underlying mechanism. In this study, we provide evidence that TIP60 plays an essential role in both NER and ICL repair pathways. We show that TIP60 directly interacts with and acetylates XPF at Lys911 following both UV irradiation and MMC treatment. We further show that this acetylation is essential for UV- or MMC-induced XPF-ERCC1 interaction and the subsequent full assembly and activation of the complex. Given the central role of the XPF-ERCC1 complex in NER and ICL repair pathways, it is not surprising that TIP60-deficient cells are hypersensitive to UV irradiation and MMC treatment. Our results offer a previously uncharacterized molecular mechanism underlying the tumor suppressor activity of the acetyltransferase TIP60. Notably, besides XPF, many other proteins can also be acetylated by TIP60, including ATM, p53, and histone proteins. Thus, it is not surprising that TIP60 has various XPF-ERCC1-independent functions. For example, while XPF- or ERCC1-null mice are viable but show a severe postnatal growth defect, mice deficient for TIP60 are early embryonic lethal.
In addition to NER and ICL repair, the XPF-ERCC1 complex is suggested to play a critical role in the regulation of chromatin looping, gene expression, as well as CTCF-mediated genome organization45,46. Given that TIP60 facilitates the XPF-ERCC1 complex assembly and activation, it would therefore be worthwhile to investigate whether TIP60 is also involved in regulating these processes in the future studies. Protein lysine acetylation is a reversible and dynamic post-translational modification. In the present study, we show that acetylation of XPF is reversibly controlled by the deacetylase SIRT1. SIRT1 directly interacts with and deacetylates XPF both in vitro and in cells. In addition to XPF, SIRT1 has also been shown to deacetylate and interact with another key NER factor XPA47. These results suggest that SIRT1 has multiple roles in NER. Of note, a previous study revealed that SIRT1 activity could be negatively regulated by genotoxic stress, such as IR, etoposide, and H2O244. Mechanistically, ATM kinase, activated by DNA damage, directly phosphorylates DBC1 at Thr454, a widely known negative regulator of SIRT1, to enhance its interaction with SIRT1, resulting in the inhibition of SIRT1 activity44. Strikingly, we found that, following UV irradiation or MMC treatment, DBC1 also binds more tightly to SIRT1, indicating that the stress-induced SIRT1-DBC1 interaction is a general mechanism for restraining the activity of SIRT1 in response to genotoxic stress. It was previously described that autoacetylation of TIP60 in response to UV damage is critical for its activation and that this activation is negatively regulated by SIRT148. Thus, inhibition of SIRT1 activity by genotoxic stress has both direct (SIRT1 as a deacetylase for XPF) and indirect (SIRT1 as a deacetylase for TIP60) roles in the regulation of XPF acetylation. Based on these results, we propose the following working model. In the absence of DNA damage, SIRT1 physically interacts with XPF and maintains XPF in the nonacetylated state. Nonacetylated XPF interacts with ERCC1 solely via its C-terminal HhH motifs due to the formation of a salt bridge between Glu907 and Lys911, leading to incomplete assembly of the XPF-ERCC1 protein complex. Upon UV irradiation or MMC treatment, activated ATM kinase phosphorylates DBC1 at Thr454 to enhance its binding to SIRT1, which in turn inhibits SIRT1 activity and thereby contributes to XPF acetylation. Once acetylated, the salt bridge between Glu907 and Lys911 is disrupted, resulting in exposure of a second binding site for ERCC1 and subsequent full assembly and activation of XPF-ERCC1 (Fig. 7h). Our findings have uncovered a mechanism underlying XPF-ERCC1 complex assembly and activation in response to DNA damage.
While UV irradiation or MMC treatment is able to trigger a strong dose-dependent induction of XPF acetylation, other DNA-damaging agents, such as IR, fail to do so. However, upon exposure to IR, TIP60 is activated. IR can also induce the interaction between SIRT1 and its inhibitor DBC1. These results indicate that, in addition to activating TIP60 and inhibiting SIRT1, there are likely other mechanisms involved in the regulation of acetylation levels of XPF following UV irradiation or MMC treatment.
Methods
Antibodies
Anti-XPF (1:1000) polyclonal antibody was generated by immunizing rabbits with MBP-XPF (residues 616–916) fusion proteins purified from E. Coli (HuaAn Biotechnology, Hangzhou, China). Antisera were affinity-purified using AminoLink plus Immobilization and purification kit (Pierce). Anti-CPD (NM-DND-001, 1:600) and anti-(6–4)PP (NM-DND-002, 1:600) antibodies were purchased from MBL International Corporation. Anti-TIP60 (ARG65853, 1:500) antibody and anti-acetyl lysine (9441S, 1:1000) antibodies were purchased from Arigo Biolaboratories and Cell Signaling Technology, respectively. Anti-phospho-ATM (S1981) (ab81292, 1:1000), anti-ERCC1 (ab129267, 1:2,000), anti-ATRIP (ab175221, 1:500), and anti-SIRT1 (ab32441, 1:1000) antibodies were purchased from Abcam. Anti-Myc (9E10, 1:1000) and anti-Flag (Clone M2, 1:10,000) antibodies were purchased from Covance and Sigma, respectively. Anti-GAPDH (MAB374, 1:3000) and anti-H3 (04–928, 1:500) antibody was purchased from Millipore. Anti-DBC1 (A303-942A, 1:1000) and anti-PCNA (SC-56, 1:500) antibodies were purchased from Bethyl Laboratories and Santa Cruz, respectively. The site-specific AcK911-XPF (1:300) antibody was generated using the following peptide: aa 905–916 FAEVVSK (Ac)GKGKK.
Cell culture and shRNAs
HeLa and HEK293T cells were purchased from ATCC and grown in DMEM (Gibco) supplemented with 10% fetal bovine serum and 1% penicillin and streptom ycin (Life Technologies) at 37 °C in 5% CO2 atmosphere. Lentivirus-based shRNAs were purchased from Thermo Fisher. The shRNA nontarget sequence is: 5′-CCCATAAGAGTAATAATAT-3′; The TIP60 targeting sequences are: #1, 5′-CCTTGACCATAAGACACTGTA-3′; 2#, 5′-CCTCCTATCCTATCGAAGCTA-3′; The SIRT1 targeting sequences are: 1#, 5′-CAGGTCAAGGGATGGTATTTA-3′; 2#, 5′-CATGAAGTGCCTCAGATATTA-3′. The shRNA-resistant wild-type and mutant TIP60 constructs were generated by changing seven nucleotides in the shRNA#2 targeting region (C1230A, C1231T, C1233A, A1236G, C1239A, T1242C, C1243A, A1245G, A1246T, G1247C, and C1248A substitutions). Lentiviruses were generated in HEK293T cells. Briefly, the shRNA plasmids were co-transfected with the packaging plasmids pMD2G and pSPAX2 into HEK293T cells. After 48 h of transfection, the viral supernatant was used to infect HeLa cells. Infected HeLa cells were then selected with media containing puromycin (2 μg ml−1, Sigma).
CRISPR/Cas9 knockout
The following guide RNAs were used to generate XPF knockout HeLa cells: XPF#1: GCCATGGCAATCCGTCGAGC; XPF#2: GCTGGAGTACGAGCGACAGC. The gRNA sequences were cloned into the pX462-pSpCas9n(BB)-2A-Puro vector (a gift from Dr Feng Zhang) according to a standard protocol. The resulting gRNA/Cas9 expression plasmids were transfected into HeLa cells. After 24 h of transfection, cells were selected with puromycin (2 μg ml−1, Sigma) and the resulting single colonies were picked and expanded. The XPF knockout clones were confirmed by immunoblotting with anti-XPF antibody.
TAP of SFB-tagged protein complexes and mass spectrometry
HEK293T cells stably expressing SFB-tagged TIP60 or XPF were lysed in NETN buffer (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, and 0.5% Nonidet P-40) containing protease inhibitors on ice for 30 min. Crude lysates were clarified by centrifugation at 15,000 × g, 4 °C for 10 min and the resulting supernatant was incubated with streptavidin-conjugated beads (GE Healthcare) at 4 °C for 3 h on the rotator. After three times washing with NETN buffer, the bead-bound proteins were eluted with biotin (2 mg ml−1, Sigma). The elutes were then incubated with S-protein beads (EMD Millipore) at 4 °C for 3 h on the rotator. After three times washing with NETN buffer, the immunocomplexes were boiled in 2 X SDS loading buffer, resolved on SDS-PAGE, and analyzed by mass spectrometry. TAP of TIP60 or XPF was performed once.
Digested peptides were dissolved in buffer A (1.9% acetonitrile, 0.1% formic acid, 98% H2O) and loaded on analytical column (150 μm × 15 cm, 1.9 μm C18) with Easy-nLCsystem. Samples were analyzed with a 60 min gradient at flow rate 300 nl min−1 as follows: 8–11% buffer B (99.9% acetonitrile, 0.1% formic acid) for 8 min, 11–20% buffer B for 40 min, 20–30% buffer B for 20 min, 30–95% buffer B for 1 min, 95% B for 6 min. Thermo Orbitrap Fusion mass spectrometer was operated in data-dependent mode with one full MS scan at R = 120,000 (m/z 200), followed by twenty HCD MS/MS scans at R = 15,000, NCE = 27, with an isolation width of 1.6 m/z. The AGC targets for MS1 and MS2 scans were 3 × 106 and 2 × 104, respectively, and the maximum injection time for MS1 and MS2 were 80 ms and 20 ms, respectively. Dynamic exclusion was set to 45 s. Mass spectrometry data were searched by MaxQuant (version 2.3). Human protein database was downloaded from NCBI (https://www.ncbi.nlm.nih.gov/). Tolerance of precursor ions and fragment ions were set to 10 ppm and 20 ppm, and maximum miscleavage sites was 2. For pull-down experiments, variable modifications were Acetyl (Protein N-term), Oxidation (M). For acetyl proteomics experiments, variable modifications were Acetyl (Protein N-term), Oxidation (M) and Acetyl (K). FDR of peptide lever and protein level were both 1%.
Plasmids and transfection
Most of the cDNAs were cloned into pDONR201 or pDONR221 vector (Invitrogen), and subsequently were transferred to gateway-compatible destination vectors. Point or deletion mutants were generated by site-directed mutagenesis kit (Stratagene) according to the manufacturer’s instructions. SFB-tagged SIRT1 plasmid was a gift from Dr Ja-Eun Kim (Kyung Hee University, Korea). All plasmids used in this study were verified by sequencing. Plasmids were transfected into human cells using polyetherimide.
Co-immunoprecipitation and western blotting
HEK293T cells were transiently transfected with SFB- and/or myc-tagged expression vectors. After 24 h of transfection, cells were washed once with 1 X PBS, lysed with NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40) containing 20 mM NaF, and 1 μg ml−1 of pepstatin A and aprotinin on ice for 30 min, and then sonicated. The resulting whole-cell lysate was clarified by centrifugation and the supernatant (~0.3 mg protein) was incubated with S-protein beads for 3 h at 4 °C on a rotator. S-protein beads were then washed three times with NTEN buffer, boiled in 2 X SDS loading buffer, and resolved on SDS-PAGE. Membranes were blocked in 5% milk in TBST buffer and then probed with indicated antibodies. All of uncropped blots are available in source data file.
Cell survival assays
HeLa Cells (5 × 102) were plated into 60-mm dishes in triplicates and incubated for 24 h before exposure to various doses of UV or MMC as indicated. After 24 h, the medium was replaced with fresh medium. Cells were then cultured for 2 weeks and colonies were fixed and stained with Coomassie blue.
In vitro acetylation and deacetylation assays
MBP-tagged wild-type XPF or the K911R mutant proteins purified from E. Coli were incubated with recombinant GST-tagged TIP60 in reaction buffer (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 4 mM MgCl2, 0.1 mM EDTA, 1 mM DTT and 10% glycerol) in the absence or presence of acetyl-CoA (2 mM) at 37 °C for 30 min. Reactions were then subjected to SDS-PAGE and immunoblotted with anti-acetyl lysine antibody. For in vitro deacetylation assay, MBP-tagged XPF purified from E. Coli were acetylated by recombinant GST-tagged TIP60 in vitro. Subsequently, acetylated XPF was incubated with recombinant SIRT1 in the presence of 5 mM NAD+ at 37 °C for 30 min. Reactions were then subjected to SDS-PAGE and immunoblotted with anti-acetyl lysine antibody.
Local UV irradiation
HeLa cells on coverslips were covered with an Isopore polycarbonate membrane filter (pore size, 5 μm; Millipore) and were then UV irradiated (254 nm). The filter was then removed and cells were cultured for the indicated time. After washing with PBS, cells were fixed with 3% formaldehyde for 10 min, permeabilized with 0.5% Triton X-100 for 5 min, and treated with 2.5 M HCl for 10 min to denature the DNAs. Subsequently, cells were blocked with BSA and incubated with primary anti-CPD or anti-6-4PP antibodies for 30 min at room temperature. After three times washing with PBS, secondary antibody was incubated for 30 min at room temperature. Nuclear DNA were then stained with DAPI. Cell images were taken on a fluorescence microscope (Eclipse 80i; Nikon) equipped with a Plan Fluor 60 X oil objective lens (NA 0.5–1.25; Nikon) and a camera (CoolSNAP HQ2; PHOTOMETRICS) and analyzed using Adobe Photoshop CS5.
6-4PP- and CPD-removal assays
Cells were irradiated with UV (at 20 J m−2 for 6-4PP or at 10 J m−2 for CPD) and then allowed to repair for indicated times in fresh medium. Cells were collected and genomic DNA was purified. The remaining 6-4PP and CPD was measured by ELISA (OxiSelectTM UV-induced DNA damage ELISA kit, CELL BIOLABS, INC., STA-332-C).
Recombinant protein purification
MBP-tagged XPF, GST-tagged TIP60 or GST-tagged SIRT1 expression constructs were transformed into E. coli BL21. Cells were then grown at 37 °C until log phase, and were induced with 0.1 mM IPTG at 16 °C for 12 h. Subsequently, cells were harvested, resuspended in lysis buffer (20 mM Tris-HCL [PH 7.5], 300 mM NaCl, 1% Triton X-100, and 1 μg ml−1 each of leupeptin and aprotinin), and sonicated. The lysate was then clarified by centrifugation and the supernatant was incubated with amylose resin or glutathione-Sepharose resin for 8 h at 4 °C. After washing the beads three times with washing buffer (20 mM Tris-HCL [PH 7.5], 500 mM NaCl, 0.5% NP-40, and 1 μg ml−1 each of leupeptin and aprotinin), the bound proteins were used for GST pull-down assays or eluted with washing buffer containing 10 mM Maltose or 20 mM Glutathione for in vitro acetylation or deacetylation assays.
Peptide-binding assay
XPF-K911 non-acetyl-peptides (FAEVVSKGKGKK) or acetyl-peptides (FAEVVSK (Ac)GKGKK) were conjugated to agarose beads according to the manufacturer’s instructions (Thermo Scientific, no. 20505). Beads conjugated with peptides were incubated with HEK293T whole-cell lysates at 4 °C for 4 h. Beads were then washed with NETN buffer, boiled in 2 X SDS loading buffer, and resolved on SDS-PAGE.
Real-time PCR
Total RNA was extracted using Trizol (Ambion, Life Technologies) and reverse-transcribed into cDNA using PrimeScript RT Master Mix (Takara, no. RR036Q). Real-time PCR was conducted using a Power SYBR Green PCR Master Mix (Applied Biosystems, Thermo Fisher Scientific, no. 4367659) with ABI 7500 RealTime PCR system (Applied Biosystems). Primers used in real-time PCR were as follows: GAPDH Forward: 5′-CGAGATCCCTCCAAAATCAA-3′; GAPDH Reverse: 5′-ATCCACAGTCTTCTGGGT GG-3′; TIP60 Forward: 5′-GGGCACCATCTCCTTCT TTGA-3′; TIP60 Reverse: 5′-ACGTAGAAGAGGAAAGGGTCTG-3′; Tublin β Forward: 5′-GCTGGACCGCATCTC TGTGT-3′; Tublin β Reverse: 5′-ACCTGAGCGAACAGA GTCCA-3′; SIRT1 Forward: 5′-CCAGAACATAGACACGCTGGA-3′; SIRT1 Reverse: 5′-TCCTCGTACAGCTTCA CAGTC-3′; XPF Forward: 5′- TTGTGAGGA AACTGTATCTGTGG-3′; XPF Reverse: 5′-AGCAAGCATGGTAGGTGTCA-3′; ERCC1 Forward: 5′- GCGACGTAATTCCCGA CTATG-3′; ERCC1 Reverse: 5′- GACCCGCAAGGCGAAGTT-3′.
Statistics and reproducibility
Data in bar and line graphs represent mean ± SEM. Information about statistical tests is provided in the figure legends. All western blot assays shown in this study were successfully repeated at least three times. Significance is indicated by asterisk (*P < 0.05, **P < 0.01, ***P < 0.001) and P value < 0.05 was considered statistically significant.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
We thank all members of the Liu group for insightful discussions. This work was supported by National Key Research and Development Program of China [2018YFC1004900 and 2018YFC2000100], National Natural Science Foundation of China [31822031, 31970664, 31670818, 81661128008, 31571397, 31730021, 31971220, 31961160725], Zhejiang Science Foundation for Distinguished Young Scholars [LR18C070001], Fok Ying Tung Education Foundation, and Fundamental Research Funds for the Central Universities [2019XZZX004-14].
Source data
Author contributions
J.W., H.H., B.C., B.Y., G.Z. and C.Z. performed the experiments; H.J. and J.C. provided essential experimental materials; T.L., L.C., G.J. and J.H. designed the experiments, analyzed the data, and wrote the manuscript.
Data availability
Mass spectrometry results are provided in Supplementary Data 1 and Supplementary Data 2, however the raw mass spectrometric data are no longer available. Source Data file contains the raw data underlying all reported averages in graphs and charts, and uncropped versions of blots presented in the figures. Additional information is available from the authors upon reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Peer review information Nature Communications thanks Frederic Coin and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary information is available for this paper at 10.1038/s41467-020-14564-x.
References
- 1.Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179–204. doi: 10.1016/j.molcel.2010.09.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078. doi: 10.1038/nature08467. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Park CH, Bessho T, Matsunaga T, Sancar A. Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease. J. Biol. Chem. 1995;270:22657–22660. doi: 10.1074/jbc.270.39.22657. [DOI] [PubMed] [Google Scholar]
- 4.Sijbers AM, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996;86:811–822. doi: 10.1016/S0092-8674(00)80155-5. [DOI] [PubMed] [Google Scholar]
- 5.De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell. Biol. 2000;20:7980–7990. doi: 10.1128/MCB.20.21.7980-7990.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Niedernhofer LJ, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol. Cell. Biol. 2004;24:5776–5787. doi: 10.1128/MCB.24.13.5776-5787.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Wang AT, et al. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev. 2011;25:1859–1870. doi: 10.1101/gad.15699211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Volker M, et al. Sequential assembly of the nucleotide excision repair factors in vivo. Mol. Cell. 2001;8:213–224. doi: 10.1016/S1097-2765(01)00281-7. [DOI] [PubMed] [Google Scholar]
- 9.Prasher JM, et al. Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient Ercc1-/- mice. EMBO J. 2005;24:861–871. doi: 10.1038/sj.emboj.7600542. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes. Carcinogenesis. 2000;21:453–460. doi: 10.1093/carcin/21.3.453. [DOI] [PubMed] [Google Scholar]
- 11.Bogliolo M, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am. J. Hum. Genet. 2013;92:800–806. doi: 10.1016/j.ajhg.2013.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Jaspers NG, et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am. J. Hum. Genet. 2007;80:457–466. doi: 10.1086/512486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kashiyama K, et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am. J. Hum. Genet. 2013;92:807–819. doi: 10.1016/j.ajhg.2013.04.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Kuraoka I, et al. Repair of an interstrand DNA cross-link initiated by ERCC1-XPF repair/recombination nuclease. J. Biol. Chem. 2000;275:26632–26636. doi: 10.1074/jbc.C000337200. [DOI] [PubMed] [Google Scholar]
- 15.Hodskinson MR, et al. Mouse SLX4 is a tumor suppressor that stimulates the activity of the nuclease XPF-ERCC1 in DNA crosslink repair. Mol. Cell. 2014;54:472–484. doi: 10.1016/j.molcel.2014.03.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Klein Douwel D, et al. XPF-ERCC1 acts in Unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol. Cell. 2014;54:460–471. doi: 10.1016/j.molcel.2014.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Klein Douwel D, Hoogenboom WS, Boonen RA, Knipscheer P. Recruitment and positioning determine the specific role of the XPF-ERCC1 endonuclease in interstrand crosslink repair. EMBO J. 2017;36:2034–2046. doi: 10.15252/embj.201695223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Abdullah UB, et al. RPA activates the XPF-ERCC1 endonuclease to initiate processing of DNA interstrand crosslinks. EMBO J. 2017;36:2047–2060. doi: 10.15252/embj.201796664. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J. Biol. Chem. 1996;271:8285–8294. doi: 10.1074/jbc.271.14.8285. [DOI] [PubMed] [Google Scholar]
- 20.Aboussekhra A, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995;80:859–868. doi: 10.1016/0092-8674(95)90289-9. [DOI] [PubMed] [Google Scholar]
- 21.de Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH. DNA structural elements required for ERCC1-XPF endonuclease activity. J. Biol. Chem. 1998;273:7835–7842. doi: 10.1074/jbc.273.14.7835. [DOI] [PubMed] [Google Scholar]
- 22.de Laat WL, et al. DNA-binding polarity of human replication protein A positions nucleases in nucleotide excision repair. Genes Dev. 1998;12:2598–2609. doi: 10.1101/gad.12.16.2598. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Tripsianes K, et al. The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair. Structure. 2005;13:1849–1858. doi: 10.1016/j.str.2005.08.014. [DOI] [PubMed] [Google Scholar]
- 24.Tsodikov OV, Enzlin JH, Scharer OD, Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1. Proc. Natl Acad. Sci. USA. 2005;102:11236–11241. doi: 10.1073/pnas.0504341102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Choi YJ, et al. Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex. J. Biol. Chem. 2005;280:28644–28652. doi: 10.1074/jbc.M501083200. [DOI] [PubMed] [Google Scholar]
- 26.de Laat WL, Sijbers AM, Odijk H, Jaspers NG, Hoeijmakers JH. Mapping of interaction domains between human repair proteins ERCC1 and XPF. Nucleic Acids Res. 1998;26:4146–4152. doi: 10.1093/nar/26.18.4146. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Xu Y, Price BD. Chromatin dynamics and the repair of DNA double strand breaks. Cell Cycle. 2011;10:261–267. doi: 10.4161/cc.10.2.14543. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Gorrini C, et al. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature. 2007;448:1063–1067. doi: 10.1038/nature06055. [DOI] [PubMed] [Google Scholar]
- 29.Sun Y, et al. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat. Cell Biol. 2009;11:1376–1382. doi: 10.1038/ncb1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Sun Y, Jiang X, Chen S, Fernandes N, Price BD. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl Acad. Sci. USA. 2005;102:13182–13187. doi: 10.1073/pnas.0504211102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Legube G, et al. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBO J. 2002;21:1704–1712. doi: 10.1093/emboj/21.7.1704. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Cheng Z, et al. Functional characterization of TIP60 sumoylation in UV-irradiated DNA damage response. Oncogene. 2008;27:931–941. doi: 10.1038/sj.onc.1210710. [DOI] [PubMed] [Google Scholar]
- 33.Kranz D, Dohmesen C, Dobbelstein M. BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways. J. Cell Biol. 2008;182:197–213. doi: 10.1083/jcb.200712014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Legube G, et al. Role of the histone acetyl transferase Tip60 in the p53 pathway. J. Biol. Chem. 2004;279:44825–44833. doi: 10.1074/jbc.M407478200. [DOI] [PubMed] [Google Scholar]
- 35.Hejna J, et al. Tip60 is required for DNA interstrand cross-link repair in the Fanconi anemia pathway. J. Biol. Chem. 2008;283:9844–9851. doi: 10.1074/jbc.M709076200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Centore RC, Yazinski SA, Tse A, Zou L. Spartan/C1orf124, a reader of PCNA ubiquitylation and a regulator of UV-induced DNA damage response. Mol. Cell. 2012;46:625–635. doi: 10.1016/j.molcel.2012.05.020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.He H, Wang J, Liu T. UV-induced RPA1 acetylation promotes nucleotide excision repair. Cell Rep. 2017;20:2010–2025. doi: 10.1016/j.celrep.2017.08.016. [DOI] [PubMed] [Google Scholar]
- 38.Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007;129:665–679. doi: 10.1016/j.cell.2007.05.003. [DOI] [PubMed] [Google Scholar]
- 39.Friedberg EC. Nucleotide excision repair of DNA: the very early history. DNA Repair. 2011;10:668–672. doi: 10.1016/j.dnarep.2011.04.018. [DOI] [PubMed] [Google Scholar]
- 40.Lou J, et al. AUNIP/C1orf135 directs DNA double-strand breaks towards the homologous recombination repair pathway. Nat. Commun. 2017;8:985. doi: 10.1038/s41467-017-01151-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Kaulich M, et al. Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi. Nucleic Acids Res. 2015;43:e45. doi: 10.1093/nar/gku1403. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature. 2008;451:583–586. doi: 10.1038/nature06500. [DOI] [PubMed] [Google Scholar]
- 43.Zhao W, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature. 2008;451:587–590. doi: 10.1038/nature06515. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Yuan J, Luo K, Liu T, Lou Z. Regulation of SIRT1 activity by genotoxic stress. Genes Dev. 2012;26:791–796. doi: 10.1101/gad.188482.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Le May N, Fradin D, Iltis I, Bougneres P, Egly JM. XPG and XPF endonucleases trigger chromatin looping and DNA demethylation for accurate expression of activated genes. Mol. Cell. 2012;47:622–632. doi: 10.1016/j.molcel.2012.05.050. [DOI] [PubMed] [Google Scholar]
- 46.Chatzinikolaou G, et al. ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes. Nat. Cell Biol. 2017;19:421–432. doi: 10.1038/ncb3499. [DOI] [PubMed] [Google Scholar]
- 47.Fan W, Luo J. SIRT1 regulates UV-induced DNA repair through deacetylating XPA. Mol. Cell. 2010;39:247–258. doi: 10.1016/j.molcel.2010.07.006. [DOI] [PubMed] [Google Scholar]
- 48.Wang J, Chen J. SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. J. Biol. Chem. 2010;285:11458–11464. doi: 10.1074/jbc.M109.087585. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Mass spectrometry results are provided in Supplementary Data 1 and Supplementary Data 2, however the raw mass spectrometric data are no longer available. Source Data file contains the raw data underlying all reported averages in graphs and charts, and uncropped versions of blots presented in the figures. Additional information is available from the authors upon reasonable request.